



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



## Teplizumab

## Chemical Properties

CAS No. : 876387-05-2  
Formula:  
Molecular Weight:  
Appearance: no data available  
Storage: store at low temperature  
store at -20°C

## Teplizumab

## Biological Description

|               |                                                                                                                                                                                                                |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description   | Teplizumab (MGA-031) is a humanized monoclonal antibody against CD3 that slows the loss of beta cell function. Teplizumab is used to treat type 1 diabetes.                                                    |
| Targets(IC50) | Others                                                                                                                                                                                                         |
| In vitro      | Teplizumab induces human CD8+ T-cell proliferation (10 ng/mL-10 µg/mL, 5 days)[3]. Teplizumab increases the expression of CD25 and intracellular CTLA4 on CD8+ cells (freshly isolated PBMCs) after 6 days[2]. |
| In vivo       | In NSG mice, Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablates the treatment effects of the drug on graft survival[3].                                    |

## Reference

Kevan C Herold, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481